AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01910441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride 1-6 mg once daily
Study NCT01910441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin (1000-1500 mg daily)
Study NCT01910441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin (1000-1500 mg daily)
Study NCT02691338 — intervention group
Intervention type: OTHER
Intervention: EEG
Description: EEG analysis
Study NCT02691338 — intervention group
Intervention type: OTHER
Intervention: Routine follow up tests
Description: Routine tests for patients after CVA. This include: neurologic evaluation, Brain CT, Angiography
Study NCT03060928 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic Rotator Cuff Repair
Description: Arthroscopic Rotator Cuff Repair
Study NCT03060928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic Rotator Cuff Repair
Description: Arthroscopic Rotator Cuff Repair
Study NCT03060928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-perforations
Description: Biological stimulation with micro-perforations
Study NCT01315821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 3 months
Study NCT01891045 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OQ-45.2 no feedback
Description: Completion of the OQ-45.2 before each session, but no feedback to therapists or patients
Study NCT01891045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OQ-45.2
Description: Completion of the OQ-45.2 with real-time feedback to the therapist and full use of the suggested interventions every week of the treatment program
Study NCT00663949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Captopril
Description: 25 mg captopril tablet q8h
Study NCT00663949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Captopril + Pentoxifylline
Description: patients takes captopril tablets 25 mg q8h and pentoxifylline 400 mg q8h
Study NCT03060928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Artelon®
Description: Biological stimulation with Artelon® Tissue Reinforcement
Study NCT02896842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posology dose modification
Study NCT04200612 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-control group
Description: This group will only be watching movies related to horses and they are told that this is another form of EAP even though this is not the case. This type of intervention has not been known to provide any therapeutic effect relevant to the study and thus is used as the placebo-control.
Study NCT02415309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 mg Melatonin
Description: 40 patients will randomly receive 2 mg melatonin
Study NCT02415309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10mg Melatonin
Description: 40 patients will randomly receive 10 mg melatonin
Study NCT02415309 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40 patients will randomly receive a placebo/sugar pill
Study NCT05426148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®
Description: The bivalent HPV 16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with aluminum adjuvant.
Study NCT02220387 — intervention group
Intervention type: OTHER
Intervention: exposure to respirable silica dust
Description: History of exposure to respirable silica dust due to job
Study NCT02220387 — intervention group
Intervention type: OTHER
Intervention: exposure to polycyclic aromatic hydrocarbons exhaust
Description: history of exposure to polycyclic aromatic hydrocarbons exhaust due to job
Study NCT02747784 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training program RehaCom®
Description: Cognitive training program RehaCom®
Study NCT02747784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training program RehaCom®
Description: Cognitive training program RehaCom®
Study NCT02941367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study NCT02941367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfonylurea
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02941367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02941367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02941367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: basal insulin
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study NCT02941367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: basal insulin
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study NCT00235157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting Palmaz Genesis peripheral stent
Description: treatment of renal artery stenosis with a renal stent
Study NCT02896842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active comparator
Study NCT03175939 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: External beam radiotherapy with curative intent, at least 66 Gy
Study NCT03175939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin IV injection over 3 hours
Study NCT03175939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU IV 24 hours continuous infusion
Study NCT00168298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 700 µg Dexamethasone
Description: 700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
Study NCT00168298 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 700 µg Dexamethasone
Description: 700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
Study NCT00168298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 350 µg Dexamethasone
Description: 350 µg Dexamethasone intravitreal implant administered on Day 0.
Study NCT00168298 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Injection
Description: Sham injection on Day 0.
Study NCT02338830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Women received vaginal progesterone suppositories (Cyclogest®, Actavis, Barnstaple, EX32 8NS, United Kingdom) in a dose of 400 mg daily beginning at 20-24 weeks gestational age
Study NCT04253730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Stress
Description: 60-90 mins of cooling via a liquid perfused suit circulating \~4-10°C liquid.
Study NCT04831112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Honey
Description: Dressing of necrotizing fascitis wounds with honey.
Study NCT04831112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Honey
Description: Dressing of necrotizing fascitis wounds with honey.
Study NCT04831112 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: EUSOL
Description: Dressing of necrotizing fascitis wounds with EUSOL.
Study NCT04831112 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EUSOL
Description: Dressing of necrotizing fascitis wounds with EUSOL.
Study NCT00927043 — intervention group
Intervention type: OTHER
Intervention: Epidemiological study according to clinical practice
Description: Epidemiological study according to clinical practice.
Study NCT02397252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eve Medical self-collection system©
Description: The Eve collection system is a plastic device not much bigger than a tampon that is inserted in the vaginal cavity. A silicone brush is then swiped around the vagina to scrape a few vaginal cells for cervical cancer screening.
Study NCT02397252 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: cobas® PCR Female swab self-sampling
Description: Regular polyester swab for collection of vaginal cells.
Study NCT02397252 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Physician-collected sampling
Description: Routine colposcopy sample collected by a physician.
Study NCT02966314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Omalizumab 300mg subcutaneous injection once monthly for 6 months. Total dose will be divided into two 150mg/1.2mL injections.
Study NCT02966314 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo Group (Sodium Chloride 0.9%) two 1.2mL subcutaneous injections once monthly for 6 months.
Study NCT03784378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXDX-105
Description: RXDX-105 capsules will be administered orally on a continuous daily dosing regimen. Patients will be continue to be treated at the dose level they were previously treated on during participation on Study of RXDX-105.
Study NCT01474577 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: Patients will complete one questionnaire over the phone. We will ask patients to describe their cardiac history since Rb-82 PET (chest pain, shortness of breath, cardiac catheterization, and heart attack). This information will be correlated to the scan results and other relevant information in the patient's medical record.
Study NCT00391976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation 300 mg
Description: Tobramycin solution for inhalation was supplied in 5 mL liquid-filled low-density polyethylene ampoules containing 300 mg tobramycin. Patients used a nebulizer to inhale the contents of the ampoules.
Study NCT03849729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine
Description: This is a randomized, control trial to investigate the effect and safety of Phentermine in patients with obesity who need a bariatric surgery (BMI >35 kg/m2 with comorbidities or BMI > 40 kg/m2).
Study NCT03849729 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: his is a randomized, control trial to investigate the effect and safety of Phentermine in patients with obesity who need a bariatric surgery (BMI >35 kg/m2 with comorbidities or BMI > 40 kg/m2).
Study NCT02582515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Study NCT02582515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00573599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prochlorperazine and benadryl IV
Description: prochlorperazine and benadryl IV, saline subQ
Study NCT00573599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imitrex SubQ, saline IV
Description: Imitrex SubQ, saline IV
Study NCT01196000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional laparoscopic surgery
Description: operation using conventional laparoscopic techniques
Study NCT01196000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robotic-assisted laparoscopic surgery
Description: operation that involves use of laparoscopic assistance with robotic assistance
Study NCT01196000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01196000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01196000 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01196000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01274039 — intervention group
Intervention type: DRUG
Intervention: Acetazolamide for glaucoma patients to lower eye pressure
Description: Acetazolamide tablets 3 times daily for 3 to 4 weeks
Study NCT04052503 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Knowledge Broker
Description: Tailored knowledge translation intervention that included barrier assessment and intervention mapping using the theoretical domains framework and participant engagement either fully or partially supported by the knowledge broker.
Study NCT04052503 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Knowledge Broker
Description: Tailored knowledge translation intervention that included barrier assessment and intervention mapping using the theoretical domains framework and participant engagement either fully or partially supported by the knowledge broker.
Study NCT02527109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Study NCT02527109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nifedipine
Study NCT02821728 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Participants in this group will consume three portions of broccoli and stilton soup per week for a minimum of four weeks before their scheduled template prostate biopsy. The soup will be made with a specially cultivated broccoli known as Beneforte, which contains an enhanced dose of a substance called glucoraphanin.
Study NCT02821728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal diet
Description: Participants in this group will continue with their normal diet up until the day of their scheduled template prostate biopsy.
Study NCT01379222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endurant Stent Graft System
Description: The Endurant Stent Graft System is designed to treat infrarenal abdominal aortic aneurysms using an endovascular approach. When placed within the aneurysm, the Endurant Stent Graft is designed to provide a permanent, alternative conduit for blood flow within the patient's vasculature by excluding the aneurysmal sac from blood flow and pressure.
Study NCT03183986 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy
Description: Phototherapy for 24 hours.
Study NCT03429712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual-source multi-detector computed tomography (DSSE)
Description: Dose split technique in a cohort of pediatric patients to determine, without increase in patient radiation dose, the optimal patient-specific and task-specific radiation dose levels for pediatric cardiothoracic and abdominal CT applications.
Study NCT03944330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: standard hospital diet
Description: patients were provided standard hospital diet that provided 25-30 kcal/kg/day
Study NCT04086186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine Peri-articular Injection
Description: A 20mL solution of 266mg of liposomal bupivacaine (Exparel) was mixed with 40mL of normal saline, which was then infiltrated consistently in the posterior capsule, medial and lateral side of the arthrotomy, patella tendon, quadriceps tendon, quadriceps musculature, and subcutaneous soft tissue.
Study NCT04086186 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block
Description: Anesthesiologist performs preoperative adductor canal block using 15mL of 0.5% Bupivacaine HCl
Study NCT03809130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Use Untire application after baseline up to 6 months
Study NCT03809130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Based Intervention
Description: Use Untire application after 3 months up to 6 months
Study NCT03809130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03809130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03809130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03809130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01152840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001 10 mg po daily medication~* Treatments will be continued until any of the following events occur:~  * progression of disease,~ * the subject develops unacceptable toxicity,~ * consent to participate in the study is withdrawn.
Study NCT00739947 — intervention group
Intervention type: OTHER
Intervention: Observational study of the surgical outcome
Description: Subjects return for 7 follow-up visits following arthroscopic repair of their rotator cuff. During the follow-up visits subjects undergo imaging with MRI and ultrasound.
Study NCT02548234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: Mirror therapy group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
Study NCT02548234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral arm training
Description: Bilateral arm training group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
Study NCT03133637 — intervention group
Intervention type: DRUG
Intervention: ceftriaxone
Description: Eligible infants will receive ceftriaxone as standard of care for sepsis
Study NCT03036085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine plus normal saline.
Study NCT03036085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with bupivacaine plus epinephrine plus normal saline.
Study NCT03036085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with bupivacaine plus epinephrine plus normal saline.
Study NCT03036085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine plus normal saline or with bupivacaine plus epinephrine plus normal saline.
Study NCT03036085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine plus normal saline or with bupivacaine plus epinephrine plus normal saline.
Study NCT04555889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lung recruitment maneuver (LRM) with DrageerVN500
Description: interventions involving device that may help to gradually lung development
Study NCT02957994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide fumarate
Description: Patients on TDF will be switched to TAF
Study NCT03155425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: A humanized monoclonal immunoglobulin
Study NCT02167386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced PrEP Adherence
Study NCT02167386 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard PrEP Adherence
Study NCT04055584 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sputum
Description: DNA extraction and perform a diversity of molecular diagnostic tests
Study NCT00446563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: 160 mg film coated tablets taken orally once daily in the morning.
Study NCT00446563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 5 mg or 10 mg tablets taken orally once daily in the morning.
Study NCT00446563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: 12.5 mg or 25 mg tablets taken orally once daily in the morning.